Version history

{
  "field_tag": "basal-ganglia",
  "text": "What resolves this contention: Whether iMSN-restricted D2 deletion eliminates dyskinesia: Quiroga reports D2 receptor activation on indirect-pathway neurons is sufficient for dyskinesia, while iMSN-D2RKO data more centrally affect lesion mortality and dyskinesia development—indicating different magnitudes of effect across models. / This effect was inhibited in both knockout models. ConclusionsWe provide experimental evidence that indirect-pathway D2 receptors significantly contribute to the expression of dyskinesia during L-DOPA treatment and mediate D2 agonist-dependent dystonic features. / Interestingly, we observed a higher mortality rate in WT as compared to iMSN-D2RKO mice in response to 6-OHDA (21.82% for WT (n = 52) versus 9.59% for iMSN-D2RKO (n = 48); Figure S1 B).",
  "source_refs": [
    "paper:paper-930888ab59a2",
    "paper:paper-f0c755975080",
    "wiki_page:computationalreviewloops-04",
    "paper:paper-930888ab59a2",
    "paper:paper-f0c755975080",
    "wiki_page:computationalreviewloops-04",
    "paper:paper-930888ab59a2",
    "paper:paper-f0c755975080",
    "wiki_page:computationalreviewloops-04"
  ],
  "importance": "0.7200",
  "tractability": "0.5500",
  "potential_impact": "0.7000",
  "composite_score": "0.2772",
  "elo_rating": "1500.00",
  "state": "open",
  "decay_rate": "0.01000",
  "resolution_evidence_refs": []
}